Paxlovid prescription associated with 51% lower hospitalization risk in US adults with COVID-19

An observational study examined the association between Paxlovid prescription and hospitalization for COVID-19 among eligible adults in the United States. The study did not report the sample size, comparator group, or follow-up duration. The primary outcome was hospitalization with COVID-19.

The main finding was that adults prescribed Paxlovid were 51% less likely to be hospitalized compared to those not prescribed the medication. The study reported only this relative effect; absolute numbers, confidence intervals, and p-values were not provided. No secondary outcomes were reported.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuation rates, were not reported. Key limitations include the observational design, which prevents causal inference, and the lack of reported absolute risk reduction. The practice relevance was not reported, and funding or conflicts of interest were not disclosed.